The advent of recombinant DNA technology and computational designing has fueled the emergence of
proteins and peptides as a new class of modern therapeutics such as vaccines, antigens, antibodies and hormones.
Demand for such therapeutics has increased recently due to their distinct pharmacodynamic characteristics of
specificity of action and high potency. However, their potential clinical applications are often hindered by involvement
of factors which impact their therapeutic potential negatively. Large size, low permeability, conformational
fragility, immunogenicity, metabolic degradation and short half-life results in poor bioavailability and inferior
efficacy. These challenges have encouraged researchers to devise strategies for effective delivery of proteins
and peptides. Recent advances made in nanotechnology are being sought to overcome aforesaid problems and to
offer advantages such as higher drug loading, improved stability, sustained release, amenability for non-parenteral
administration and targeting through surface modifications. This review focuses on elaborating the role of nanotechnology based formulations
and associated challenges in protein and peptide delivery, their clinical outlook and future perspective.
Keywords: Proteins, peptides, stability, nanocarrier, bioavailability, immunogenicity.
Rights & PermissionsPrintExport